Anthropic buys biotech startup Coefficient Bio for $400 million in stock

Anthropic has acquired stealth biotech-AI startup Coefficient Bio for $400 million in shares, as reported by The Information and independent technology journalist Eric Newcomer. This is the company's first major acquisition that goes beyond traditional AI infrastructure, and a clear signal that Anthropic is seriously targeting biological sciences as the next major arena for applying its technologies. Coefficient Bio remained virtually invisible to the public until the very end — the startup operated in stealth mode, which is atypical in itself for deals of this scale.

Nothing is publicly known about the team composition, specific developments, or product stage. $400 million in shares is a substantial sum for a company that the market essentially knew nothing about until the moment the deal closed. This suggests that Anthropic acquired primarily a team and technology, rather than a finished product with users.

For Anthropic, this acquisition fits into a broader industry trend: major AI laboratories are actively seeking ways to apply their models beyond traditional text and multimodal tasks. Biology and medicine represent one of the most promising applications: protein structure prediction, drug molecule design, genomic data analysis, cellular process modeling. All of this requires working with massive volumes of complex structured data — exactly what modern AI systems excel at.

Google DeepMind has already demonstrated what AI can achieve in this field by releasing AlphaFold — a system that solved the problem of predicting three-dimensional protein structures, which had been considered one of the key unsolved problems in biology for decades. Since then, the Bio-AI field has been experiencing rapid growth: new startups receive generous funding, and major players are building long-term strategies for presence in this sector. Anthropic positions itself as a company with special emphasis on AI safety and reliability.

This makes the biomedical direction a particularly logical step: in medicine and biology, the cost of error is critically high, requirements for result verifiability are maximum, and therefore demand for responsible AI is particularly strong here. Coefficient Bio, evidently, was working precisely in this space — at the intersection of deep machine learning and biological research. The structure of the deal — $400 million in shares rather than cash — is also telling.

This means that the startup's founders and investors receive a stake in Anthropic rather than immediate cash. This format speaks to mutual confidence: the Coefficient Bio team believes in Anthropic's continued growth, and the company itself preserves liquidity for operating expenses and future investments. At Anthropic's last valuation of around $61 billion, this is an attractive asset for long-term holding.

What does this mean for the market as a whole? Major AI companies are entering a phase of active acquisitions — and biotech is becoming one of the priority directions. Following Anthropic, similar moves will very likely be taken by OpenAI, Google DeepMind, and other players with sufficient capital.

For startups working at the intersection of AI and life sciences, this means heightened interest from strategic buyers — and rising valuations already in early rounds. Details about Coefficient Bio's team and technological stack are expected in Anthropic's official statement in the near future.